This report aims to summarize the components of the OCTRI Pilot Awards Program, highlighting its processes, progress, key achievements, and overall impact.

**Oregon Clinical Translational Research Institute**

As a Clinical and Translational Science Award (CTSA) awardee, The Oregon Clinical and Translational Research Institute (OCTRI) is a member of a Consortium of 62 CTSA awardees housed at academic medical centers throughout the United States. At its home institution, Oregon Health & Science University (OHSU), OCTRI serves as the integrated hub for clinical and translational research and provides a coordinated infrastructure of core services to biomedical researchers.

OCTRI is funded primarily through the CTSA program. Additional funding sources include institutional commitment from OHSU and direct dollars from services provided to researchers. OCTRI also receives collaborative support from a network of on- and off-campus partners.

**The OCTRI Pilot Awards Program**

The OCTRI Pilot Awards Program provides direct funding for translational research. With the goals of fostering exciting science, providing support for preliminary data generation, and stimulating the development of translational research methodology, OCTRI pilot awards are a valuable source of scientific support for OHSU translational researchers.

**Pilot Awards Program Evaluation**

At a minimum, all OCTRI pilot awardees are required to participate in reporting and measurement of project progress and outcomes including tracking of publications, new grant funding, and commercialization outcomes derived from pilot funding. Most awardees also report qualitatively on project impact and list other forms of results dissemination. Investigator feedback and project outcome data are used to improve program management and guide decisions about future program iterations and initiatives.

**OCTRI Strategic Goals**

The OCTRI Pilot Awards Program cuts across all five of OCTRI’s strategic goals.

1. **Catalyze** translational research
2. Foster and support scientific collaboration
3. Enhance partnerships with communities
4. Cultivate innovation in research
5. Develop a translational workforce
Innovative Metrics

Improvements to Review Process
Focus on Methodology

• Targeted methodology solicitation in FY15 Catalyst RFA
• Emphasis on dissemination

Improvements to Review Process
• Implementation of cross-institutional reviews
• Increase in breadth of reviewer expertise

Innovative Metrics
• Alt-metrics
• Evaluation of dissemination methods

Opportunities

Catalyst Awards

Catalyzing Translational Research Opportunities

Each year OCTRI, with substantial investment from the School of Medicine, supports 3 to 5 awardees ($400,000 total) to facilitate novel, collaborative, multidisciplinary studies that will lead to further research and funding in translational research. This funding is specifically intended to enable the development of compelling new grant applications that will sustain the proposed research activity. For example:

1. Large, transdisciplinary grant development
2. Research cohort development
3. T1 translational research/first in human studies

This funding mechanism is offered in close collaboration with the School of Medicine, but is open to all OHSU faculty.

Methodology Awards

Development of Novel Research Methodologies

The development of new methodologies is critical to the advancement of translational and clinical research. OHSU investigators are frequently involved in the creation and dissemination of translational research methods, and this program offers a dedicated funding mechanism to accelerate such work. The goal is to facilitate development of state-of-the-art tools for translational research and to make them rapidly available to investigators. Updated application and selection procedures for this opportunity are currently being finalized.

Biomedical Innovation Program

With substantial investment from OHSU, the Biomedical Innovation Program is designed to foster the development of devices and diagnostics that provide solutions to important health care problems. Critical elements of successful projects include a well-developed idea or vision for the end product and a collaboration between clinicians, scientists, and bioengineers. Expected outcomes include commercialization milestones. These collaborations make possible the identification of a significant clinical problem, an innovative idea for a device or diagnostic to address the problem, bioengineering approaches for device or diagnostic development, and early validation of effectiveness. The BIP program is offered in partnership with OHSU Tech Transfer & Business Development. BIP has also developed an important alliance with the Oregon Translational Research and Development Institute (OTRADI). OTRADI leadership and funding are instrumental to the continuing growth and development of BIP.

Strategic Investment Funding

Strategic Investment Funding supports OHSU faculty members by providing a funding mechanism that can provide a critical difference for clinical/translational research. Applications for funding are rapidly evaluated (weeks), and support will be quickly available for those selected. Priority is given to those proposals that require a small amount of funding to achieve a significant result.

This award is intended to provide critical support for a project that is close to achieving independent funding. It is meant to allow translational research projects with already well-developed study processes, but without funds, to get “over the last hurdle” and gather additional data needed for independent funding applications.

Targeted Funding

OCTRI Community & Practice Research (CPR)

The OCTRI CPR program seeks to work collaboratively with community organizations, health care practices, and researchers to study how best to improve the health of Oregonians. In 2014, OCTRI funded one project at $50,000 (highlighted on page 10).

Specimen Retrieval Opportunity with the Northwest Biobank at Kaiser Permanente Northwest

The Kaiser Permanente Center for Health Research (KPCHR) and OCTRI offer an opportunity for OHSU investigators to utilize the capacity of the NW Biobank at Kaiser Permanente. Samples will be retrieved from the Kaiser Permanente Northwest Biobank (NWBB). Specimens are currently in storage as stabilized buffy coat or DNA at -80°C. Buffy coat samples will have DNA extracted before transfer to the selected investigator for use in research. The NWBB currently has over 12,500 samples on hand for this use.

Future Plans

Focus on Methodology

• Targeted methodology solicitation in FY15 Catalyst RFA
• Emphasis on dissemination

Improvements to Review Process

• Implementation of cross-institutional reviews
• Increase in breadth of reviewer expertise

Innovative Metrics

• Alt-metrics
• Evaluation of dissemination methods

Expanded Commercialization Initiatives

• SBIR Phase 0 program
• Commercialization education
• Expansion of industry connections
• MedTech Alliance launch

Community Partnership Development

• Knight Cancer & Cardiology Centers
• OTRADI
• Portland State University
• Foundations
9 Years
5 Funding Partners
110 Principal Investigators
39 Departments
$5.8M Invested

135 Projects

267 Collaborations
110 Publications
$55.5M Follow-on Funds
15 Provisional Patents
12 Industry Partners
2 Start-up Companies
Pilot Awards Program Outcomes

Collaborations & Co-Funding

The OCTRI Pilot Awards Program is a collaborative effort. Co-funded awards active in 2014 included collaborations with the OHSU School of Medicine, OSHU Vice President for Research Office, OHSU Research Roadmap, Oregon National Primate Research Center (ONPRC), and the Oregon Translational Research & Development Institute (OTRADI). Key partnerships also include those with OHSU Leadership, Tech Transfer & Business Development, and the OHSU Division of Management. To date, OCTRI pilot awardees have reported ~127 internal (OHSU) collaborations and ~137 external (cross-institutional) collaborations resulting from pilot award projects.

Investigator Feedback

In 2014, all current and most past awardees were surveyed regarding their opinions of the OCTRI Pilot Awards Program.

Customer ratings of the awards program (n=68) response rate 88% Overall Satisfaction = 8.8/10 Expectations Met = 8.5/10 Overall Performance Rating = 8.2/10

“The process was transparent and very flexible - we had a slight change in scope and all staff at OCTRI were very helpful in shifting the emphasis of the proposed work to make most effective use of the funds.”

-Awardee

New Grant Funding & Publications

<table>
<thead>
<tr>
<th>Years Since Award Date</th>
<th>Count of Projects*</th>
<th>OCTRI Investment</th>
<th>New Funding</th>
<th>Basic ROI</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>17</td>
<td>$541</td>
<td>$893</td>
<td>0.65</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>14</td>
<td>$673</td>
<td>$1,931</td>
<td>1.87</td>
<td>9</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>$488</td>
<td>$337</td>
<td>-0.31</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>17</td>
<td>$694</td>
<td>$4,131</td>
<td>4.95</td>
<td>24</td>
</tr>
<tr>
<td>4</td>
<td>13</td>
<td>$422</td>
<td>$4,386</td>
<td>9.39</td>
<td>9</td>
</tr>
<tr>
<td>5</td>
<td>12</td>
<td>$428</td>
<td>$10,159</td>
<td>22.71</td>
<td>17</td>
</tr>
<tr>
<td>6</td>
<td>22</td>
<td>$868</td>
<td>$21,808</td>
<td>24.13</td>
<td>29</td>
</tr>
<tr>
<td>7</td>
<td>9</td>
<td>$229</td>
<td>$10,304</td>
<td>44.04</td>
<td>11</td>
</tr>
</tbody>
</table>

*projects launched prior to 2014 awards survey, with OCTRI funding (n=114)

Return on Investment

ROI=For each OCTRI dollar invested, the dollars returned in new funding. Sources of new funding include federal, industry, and foundation grants. New funding is reported by each OCTRI principal investigator and verified by OCTRI evaluation staff. Basic ROI is routinely reported by CTSAs and other NIH-funded institutes.

Projects Take Time to Show Results

For projects awarded 5 years ago, ~23 dollars have been returned in new grant funding for each OCTRI dollar invested

Average project launch to 1st publication: 26 months

Average project launch to 1st follow-on grant: 24 months
Catalyst Awards

This funding mechanism is supported by OCTRI and the OHSU School of Medicine.

The objective of the OCTRI Catalyst funding is to facilitate novel, collaborative, multidisciplinary studies that will lead to further research and funding in translational research. This funding is specifically intended to enable the development of compelling new grant applications that will sustain the proposed research activity.

OCTRI Sub-aims Addressed by the Catalyst Awards:

- Identify and support research opportunities across the translational spectrum
- Catalyze discoveries in all stages of the human lifespan
- Stimulate trans-disciplinary research with OHSU and its academic and community stakeholders

Catalyst Outcomes FY12 to FY14

Projects 11
Total follow-on awards 3
Grants totaling $1,895,361
Return on Investment 1.74
Publications 3

Catalyst ROI is currently outpacing ROI for all projects open during the same time frame.

Highlighted Outcome

Using the preliminary data generated from Dr. David Huang’s 2013 catalyst award, Dr. Yali Jia, Ph.D., was awarded an R01 titled “OCT Angiography for Neovascular Age-related Macular Degeneration.” ($1.5 M, September 2014) as well as a DP3, “Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy.” ($1 M, October 2014)

Most Recent Award Cycle Review Process

21 Reviewers
29 Letters of Intent
12 Full Applications
4 New Awards

Satisfaction Surveys

Reviewers (62% Response)
100% Considered process fair and impartial
Suggestions:
- Increase scientific diversity of reviewer pool
- Include external reviewer

Investigators submitting LOIs (52% Response)
Appreciated extensive, concrete feedback
Suggestions:
- Increase scientific diversity of reviewer pool
- Use and communicate criteria more consistently

“There is not really a way the feedback could have been more helpful. This was the most extensive feedback I’ve had in a grant application process.”

-Applicant

Types and Amounts of Grants Disbursed

Direct dollars only, per project awarded

<table>
<thead>
<tr>
<th>Year</th>
<th>Cohort Discovery</th>
<th>Center Grant Development</th>
<th>First in Human</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2015*</td>
<td>$119 K</td>
<td>$116 K</td>
<td>$99 K</td>
<td>$99 K</td>
</tr>
<tr>
<td>FY2014</td>
<td>$127 K</td>
<td>$90 K</td>
<td>$55 K</td>
<td>$272,000</td>
</tr>
<tr>
<td>FY2013</td>
<td>$104 K</td>
<td>$132 K</td>
<td>$91 K</td>
<td>$69 K</td>
</tr>
<tr>
<td>FY2012</td>
<td>$134 K</td>
<td>$132 K</td>
<td>$45 K</td>
<td>$94 K</td>
</tr>
</tbody>
</table>

*Not included in outcomes to date
Blocking Lung Disease and the Epigenetic Changes in Childhood Caused by Maternal Smoking During Pregnancy

Cynthia McEvoy, M.D., MCR, is board certified in Pediatrics and Neonatology with a clinical and research interest in pulmonary function in neonates and pediatric patients. Her research focuses on preventative measures for improving neonatal pulmonary health. Funding from a K23 enabled initial development of a cohort of pregnant women unable to quit smoking who were randomized to supplemental vitamin C (500 mg per day) or to a placebo during pregnancy. Standardized pulmonary function tests were performed on each newborn within three days of birth. Findings indicated that two important measures of lung function (the ratio of time to peak tidal expiratory flow to expiratory time and the passive respiratory compliance) were significantly better in newborns of mothers who took vitamin C compared with those who did not. Funding from the OCTRI Catalyst award has allowed Dr. McEvoy to profile the offspring cohort’s DNA methylation patterns from birth to childhood. OCTRI provided financial and nursing support to re-contact patients from the original study, financial support for materials for biomarker collections, and biostatistical and informatics support.

Findings from this work were published in JAMA in May 2014, and presented at the American Thoracic Society (“cutting edge” presentations) and European Respiratory Society meetings. The findings were also featured in Science Daily, University Herald, and Science World Report. Dr. McEvoy’s work has tremendous potential to impact human health and health economics, as Vitamin C is a simple, safe and inexpensive supplement (with continued smoking cessation counseling) that may decrease respiratory morbidity including the development of asthma in offspring of pregnant smokers.

“OCTRI is able to facilitate the rapid translation of basic science studies/discoveries into the clinical arena particularly with the infrastructure support of skilled nursing, bioinformatics, and statistics. Support from OCTRI is critical to the success of translational studies and enhances the investigator’s ability to collaborate within and across institutions.”

-Cynthia McEvoy

Oregon Animation Test for Social Reciprocity

Garet Lahvis, Ph.D., is an Assistant Professor of Behavioral Neuroscience at OHSU. Dr. Lahvis’s research has focused on the development of novel assessments for mouse social ability, including the shared affect of autism in children and mice.

Autism Spectrum Disorders (ASD) feature deficits in social interaction, communication and repetitive interests. Drug and behavioral treatments for ASD are undergoing rapid development, yet the diagnostic tools are not suitable for efficacy assessment. The current gold standard for diagnosis, the Autism-Diagnostic Observational Schedule (ADOS) is often considered to have significant drawbacks. Furthermore, the wait time to receive a clinical autism assessment and diagnosis can be one year or more.

“As a result of OCTRI Catalyst funding, Dr. Lahvis and his team are developing the Oregon Animation Test for Social Reciprocity (OATS) to evaluate distinct autistic behavioral phenotypes. During the OATS assessment, a child’s responses are analyzed. OCTRI has provided extensive IRB preparation assistance and study coordinator services. As the project nears conclusion, in 2015, OCTRI will provide biostatistics support.

In addition to introducing quantification of key behavioral phenotypes, OATS has the potential to slash wait times for autism diagnosis, develop the basis of a deeper scientific understanding of autism and to improve clinical care. The OATS test is patent pending. In October 2014, OHSU Technology Transfer & Business Development entered into an exclusive option for OATS with a medical device firm.

“It’s hard to convey the difficulties facing a mid-career basic scientist transitioning to translational research. We lack mentors, clinical experience, and understanding of the institutional requirements for human subject research. OCTRI has anticipated every single one of these obstacles, typically forewarning me of their emergence, then helped me move through them, all with an earnest willingness for me to succeed.”

-Garet Lahvis
BIOMEDICAL INNOVATION PROGRAM

This funding mechanism is offered in close collaboration with Technology Transfer & Business Development (TTBD) and Oregon Translational Research and Development Institute (OTRADI).

OCTRI Sub-aims addressed:
- Facilitate commercialization
- Create and support public-private partnerships
- Develop innovative methods for career development

Commercialization Outcomes to Date
- 6 provisional patents filed for 5 investigators
- 3 start-up companies formed
- 2 technologies optioned
- 1 industry partner contract
- 2 business plans developed

Highlighted Outcome

In 2013, neurosurgeon Dr. Neil Roundy met with designer and engineer, Rachel Dreilinger, to discuss prototype development of a bio-absorbable clip and applier to replace labor intensive suturing of the dura mater. Today, their startup company, NeuraMedica, is working with TTBD to license the technology and to bring it to the marketplace.

Highlighted Outcome

Rapid Progress

Community Partners

The BIP is part of a regional ecosystem that fosters bioscience innovation. Current and developing partnerships (in addition to OTRADI and TTBD) include, Oregon Nanoscience and Microtechnologies Institute, Oregon Bioscience Association, Technology Association of Oregon, Business Oregon, Portland State University, University of Oregon, and Oregon State University. These partners connect awardees to resources and opportunities that further product development and commercialization.

Most Recent Award Cycle Review Process

18 Reviewers, 12 Letters of Intent,
6 Full Applications, 4 Awardees

Investigator Feedback

Overall application process = 4/5
Average of individual processes questions = 2.5/3
Project management = 2.75/3

“It was helpful to have the staff put me in touch with others in the area whom I could work with, the networking was much appreciated.”

-BIP Investigator

Average Process Ratings (out of 3)

<table>
<thead>
<tr>
<th>Professionalism</th>
<th>2.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responsiveness</td>
<td>2.5</td>
</tr>
<tr>
<td>RFA Clarity</td>
<td>1.9</td>
</tr>
<tr>
<td>Duration of Process</td>
<td>2.4</td>
</tr>
<tr>
<td>Fair &amp; Impartial</td>
<td>3.0</td>
</tr>
<tr>
<td>Reviewer Feedback</td>
<td>2.8</td>
</tr>
</tbody>
</table>

Education Events

The OCTRI Pilot Awards program provides BIP awardees with support to attend, present at, and network at the following events:
- SBIR workshops
- Oregon Bioscience Association Conference and events
- Technology Association of Oregon medical device development events
- Portland State University events including Lab2Market

Funding & Development

- BIP RFA - Seed grants for OHSU investigators
- SBIR/STTR Phase 0 - Pre-submission support
- DoD Funding - Evaluation for BIP awardees
- Industry collaboration through MedTech Alliance

Facilitate Commercialization

Project Management

- Track progress
- Remove barriers
- Establish mentors and industry partnerships
- Drive next stage funding

Innovation & Entrepreneur Education

- INVENT Seminar Series - Inspirational keynotes and didactic seminars open to OHSU and community members
- Publicize in-depth courses and workshops offered by regional partners (such as OBA & PSU)

Interdisciplinary Mentors & Reviewers

- Biomedical Innovation Program committee
- OHSU faculty and staff
- Regional and business partners
- Academic partnerships with University of Oregon and Portland State University
Electronic Device to Prevent Central Line Infections

Michael Hutchens, M.D., M.A., is associate professor at OHSU and a practicing Critical Care Anesthesiologist in the Cardiac and Surgical Intensive Care Unit. As an NIH-funded scientist, his interests include the effects of sex steroids on outcomes of acute kidney injury following cardiac arrest. He is a serial inventor whose active projects include novel methods of delivering anesthesia, measuring renal function, and preventing commuter cyclist morbidity. Despite being labeled a “never event,” central line associated bloodstream infection (CLABSI) occurs 41,000 times per year in the United States, and has a mortality rate of 12 to 25%. The cost, approximately $10,000 to $20,000 per event, is borne by health care facilities because “never events” are not reimbursed by the Centers for Medicare Services. Existing strategies to reduce infection include hand hygiene, glove use, and conventional hub care, but despite wide adoption of these strategies, CLABSI is still common. Dr. Hutchens received funding to continue development of a device that provides targeted application of ultraviolet light, ensuring central venous catheters, and other medical access site catheters, are disinfected and clean. In a pilot microbiology study, staphylococcus aureus counts following use of the Hutchens device compared favorably with those after standard care, without need for human intervention.

Outcomes to date: OHSU Technology Transfer & Business Development negotiated an exclusive option agreement for this technology with a regional medical device company. Over the next year, Dr. Hutchens will be working closely with its engineering team to refine the prototype and move it toward commercialization.

“Being a physician with limited experience in the business aspect and marketing potential of this project, it was important to have people who understand and provide us with this expertise. They just make it easy for us to go to the next step.”

-Amira Al-Uzri

Designing a Convenient and Precise Device for Home Dried Blood Spot Collection

Successful organ transplantation requires life-long therapeutic drug monitoring. The current state-of-the-art methods require frequent laboratory visits for venous blood draws and subsequent analysis. There are no readily available methods for in-home collection of patient blood samples with the necessary accuracy to replace visits to the clinic. The realities of day-to-day living often result in an inconsistent testing regimen that prevents timely intervention and puts the patient at risk. There is a need for a simple, easy-to-use blood sample collection method with a demonstrated repeatability/accuracy that can substitute for a visit to the clinic. Dr. Al-Uzri and her team are developing a simple, user-friendly device that can be used alone in any environment to obtain a dried blood spot that is accurate, precise, and can be mailed without special packaging to a clinical laboratory for analysis.

Outcomes to date: Since receiving BIP funding, the OHSU team has formed a partnership with a local engineering firm, successfully developed two prototypes for use in clinical trials, and filed a provisional patent. This technology was selected as a case study for the University of Oregon’s Technology Entrepreneurship Program and received a free, comprehensive marketing plan.

Amira Al-Uzri, M.D., Principal Investigator, is a professor in Pediatrics and the Medical Director of the Pediatric Kidney Transplant Program and the Director for Clinical Research in Pediatric Nephrology at OHSU. Research interests include establishing methods to personalize medicine and health care delivery to our patients with chronic diseases in general and those with kidney diseases and transplantation in particular.

Dennis R. Koop, Ph.D., Co-Investigator, is a Ph.D. in Biochemistry from Northwestern University School of Medicine; professor in Physiology and Pharmacology and the director of the Bioanalytical Shared Resource Pharmacokinetics Core facility at OHSU. He was responsible for the development of the analytical methods for the analysis of tacrolimus and creatinine from a single dried blood spot using instrumentation in the core.

Andy Chitty, MBA, is the program manager for OHSU’s University Shared Resources. He is responsible for strategic management of several scientific service centers that meet the needs of researchers on campus. Part of his role is to develop beneficial relationships with users and collaborators outside of OHSU.

“...hard (this coming from someone with a calibrated sense of 'hard') to get an idea through the lab to the outside without a lot of dedicated help at OHSU. BIP provides that help.”

-Michael Hutchens
Bromodomain Inhibition for the Treatment of Lethal, Castration-Resistant Prostate Cancer

Joshi Alumkal, M.D., is an associate professor of Medicine and co-leader of the OHSU Prostate Cancer Research Program. His work includes both clinical research and basic bench science and focuses on metastatic castration-resistant prostate cancer (CRPC) – the uniformly lethal form of this disease. Dr. Alumkal’s research has demonstrated that the lysine specific demethylase 1 (LSD1) protein is a critical CRPC survival factor. He was awarded a Strategic Investment grant by OCTRI to conduct experiments necessary to support the resubmission of an R01 proposal. Specifically, Strategic Investment funds allowed Dr. Alumkal’s team to respond to key suggestions from reviewers of the initial submission. These critiques included: 1) The need for more mechanistic insights into how LSD1 regulates its target genes and 2) More evidence for the in vivo functional role of LSD1 in CRPC evolution.

Upon completion of work responding to the review committee and post-resubmission, Dr. Alumkal’s R01 was given a sixth percentile rank and was funded at $1.6 million. Dr. Alumkal also received a pilot project grant of $25,000 from the NIH-funded Pacific Northwest Prostate Cancer SPORE PPG-like grant based on data generated from the Strategic Investment. A manuscript describing his findings is in preparation. Dr. Alumkal hopes that his ongoing work will inform the design of a new clinical trial in patients with advanced prostate cancer with the LSD1 inhibitor he is testing in the lab.

Evaluation Impacts of Central Oregon CCO’s Complex Care Clinic

Peter Graven, Ph.D., is a health economist at OHSU’s Center for Health Systems Effectiveness (CHSE), where he studies the health system transformation in Oregon and the impact of federal health reform on individuals, employers, and the states. In addition, Peter investigates health insurance theory, tackles methodological issues, and teaches health economics as part of the OHSU-PSU School of Public Health Initiative.

In March 2014, Dr. Graven was awarded an OCTRI Community Award. The OCTRI funding allows Dr. Graven and his evaluation team to collaborate with researchers at the Central Oregon Health Council Coordinated Care Organization, PacificSource, and Mosaic Medical to access the Oregon All Payer All Claims (APAC) database. Prior to receiving the OCTRI award, the team was working with Bridges Health, collecting pre-treatment and post-treatment data on participants from a variety of sources including a survey instrument, claims data, and electronic health records. The OCTRI award allows the team to select a set of controls to measure the costs without intervention, enhancing the current evaluation with a more sophisticated methodology and additional data sources. The primary measures of interest include: health, wellness, patient activation, claims experience, health visit patterns, connection to social services, patient risk scores, and patient costs.

As a result of this emerging OHSU-COHC collaboration, the team was approached by Providence CORE and asked to engage in joint submission of a PCORI grant. This project, “Caring for the Whole Person: A Patient-Centered Assessment of Integrated Care Models in Vulnerable Populations” was recently awarded a $2.1 million PCORI grant in the Improving Healthcare Systems Winter 2014 Cycle. OHSU will receive $448,000 of the total award.
Catalyzing Translational Research Opportunities

Penelope Hogarth, M.D., associate professor, Department of Neurology
Neurodegeneration with Brain Iron Accumulation: Research Cohort Development

Garet Lahvis, Ph.D., assistant professor, Department of Behavioral Neuroscience
Oregon Animation Test for Social Reciprocity

Cynthia McEvoy, M.D., professor, Department of Pediatrics
From Mother to Baby: Blocking Lung Disease and the Epigenetic Changes in Childhood Caused by Maternal Smoking During Pregnancy

Translational Research Leading to Biomedical Commercialization

Peter Kurre, M.D., associate professor, Pediatrics and Cell & Developmental Biology
Minimally-invasive biomarkers to monitor treatment response in AML

Chris Madden, Ph.D., research assistant professor, Department of Neurological Surgery; Kim Burchiel, M.D.; Shaun Morrison, Ph.D.
Deep brain stimulation for treatment of obesity
*Outcome note: Dr. Burchiel has since formed a startup company, Ceremod, which has optioned the technology from OHSU

Linda Musil, Ph.D., associate professor, Department of Biochemistry & Molecular Biology
Device to prevent posterior capsule opacification after cataract surgery

Helané Wahbeh, N.D., MCR, assistant professor, Department of Neurology
Internet Mindfulness Meditation Intervention

Strategic Investments

Joshi Alumkal, M.D., associate professor, Knight Cancer Center
The Role of LSD1 in the Evolution of Castration-Resistant Prostate Cancer

Ganesh Cherala, Ph.D., assistant professor, OSU/OHSU College of Pharmacy
Obesity and oral contraception: Obfuscation by bioanalytical method

James Chesnutt, M.D., medical director of the OHSU Sports Medicine Program
2014 OHSU TBI/PTSD Research to Rehabilitation Scientific Symposium

Deborah Cohen, Ph.D., associate professor, Department of Family Medicine
CAA Proposal

Kim-Hien Dao, D.O., Ph.D., assistant professor, Knight Cancer Institute
Establishing a Fanconi anemia humanized mouse model to prospectively evaluate clonal evolution and leukemia transformation

Marie Pierre Hasne, Ph.D., research assistant professor, Department of Biochemistry and Molecular Biology
3D mapping of Trypanosoma cruzi infected cardiomyocytes by high-resolution electron microscopy

Peter Kurre, M.D., professor, Department of Pediatrics
Maternal high fat diet induces DNA damage in fetal hematopoietic stem cells

Christina Lancioni, M.D., assistant professor, Department of Pediatrics
Toll-Like Receptors and PBMC Specimens

Scott Landfear, Ph.D., professor, Department of Molecular Microbiology and Immunology
Phenotypic Screening for Novel Anti-leishmanial Drugs

Carol MacArthur, M.D., associate professor, Department of Otolaryngology, Head, Neck, and Surgery
Genetic Susceptibility Innate Immune Response Gene Polymorphisms in Otitis Media to Chronic Otitis Media

John Muschler, Ph.D., research associate professor, Department of Biomedical Engineering
Detection and treatment of bladder cancers through targeting altered tissue architecture

Georgina Purdy, Ph.D., research associate professor, Molecular Biology and Microimmunology
Pilot HTS for Inhibitors of Mycobacterial Biofilms

Dmitri Rozanov, Ph.D., research assistant professor, Molecular and Medical Genetics
Validation of the oxidative stress treatment in vivo in established breast cancer xenograft mouse model

Gail Wolf, Ph.D., R.N., clinical assistant professor, School of Nursing
Promoting Literacy, Promoting Health: Early Childhood & Family Literacy Project

Scott Wong, Ph.D., associate professor, Department of Molecular Microbiology and Immunology
Herpes Rhadinoviruses and Multiple Sclerosis: An Exploratory Investigation

Community

Peter Graven, Ph.D., health economist, Center for Health Systems Effectiveness
Evaluating Impacts of Central Oregon Coordinated Care Organization's Complex Care Clinic, Bridges Health
Thank you OCTRI reviewers

Bridget Adams
Joshi Alumkal
Christopher Andon
Susan Aromaa
Grover Bagby
Abhijit Banerjee
Peter Barr-Gillespie
Patricia Carney
Joseph Carroll
Sunwen Chou
Fergus Coakley
Deborah Cohen
Robert Copenhaver
Christopher Corless
Lisa Cousins
Michael Davey
Jeffery Davis
Ann Demaree*
Jennifer DeVo
Kathy Drew*
David Ellison
Lyle J. Fagnan
Jennifer Fox*
Peter Galen*
Katrina Goddard*
Jeffrey Gold
Kenton Gregory
Andras Gruber
Stephen Hall
Mary Heinricher
Robin Henderson*
Robert Hitzemann
Penelope Hogarth
Josh Hoyt*
James Huntzicker
David Jacoby
Jeffrey Jensen
Devan Kansagara
Jeffrey Kaye
Robert Kievit
Robert Klein
David Koeller
Peter Kurre
Jodi Lapidus
David Levinsohn
Jonathan Lindner
Donald Lollar
Thomas Machala*
Daniel Marks
Lynn Marshall
Dennis McCarty
Owen McCarty

James McNames*
Shannon McWeeney
Cynthia Morris
William Newman*
Carrie Nielson
Robert O’Roarke
Eric Orwoll
Zach Pangares*
Joseph Quinn
Charles Roberts
James Rudolph*
Sandra Rugonyi
Mary Samuels
Thomas Scanlan
Kathryn Schuff
Robert Schuff
Jackilen Shannon
Cailin Sibley
Sibina Smith*
Stephen Smith
Susan Smith
Eliot Spindel
Robert Steiner
Clyde Taylor
Michael Tippie*
Jeffrey Tyner

*Reviewer is external to OHSU